Floatz logo

Pyrotinib

Renal Cell Carcinoma

HiFiBiO TherapeuticsSmall moleculePhase 1/2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
65/ 100

Competitive context

144 Active assets in the Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
Fuzhou General Hospital
Phase 3BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 4BB
su011248
Peking University Cancer Hospital & Institute
Phase 4BB
Everolimus
Merck Sharp & Dohme LLC
Phase 4BB
Axitinib
SWOG Cancer Research Network
Phase 4BB

View all 50 →

Same molecule, other indications

Pyrotinib is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →